These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25922609)

  • 21. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States.
    Willey C; Gauthier-Loiselle M; Cloutier M; Shi S; Maitland J; Stellhorn R; Aigbogun MS
    Curr Med Res Opin; 2021 Jul; 37(7):1155-1162. PubMed ID: 33970726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
    Mader G; Mladsi D; Sanon M; Purser M; Barnett CL; Oberdhan D; Watnick T; Seliger S
    BMC Nephrol; 2022 Oct; 23(1):334. PubMed ID: 36258169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and risk factors for kidney failure in patients with autosomal dominant polycystic kidney disease: A retrospective study.
    Park H; Paek JH; Kim Y; Park WY; Han S; Jin K
    Medicine (Baltimore); 2022 Nov; 101(47):e31838. PubMed ID: 36451428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.
    Iyer NN; Vendetti NJ; Levy DI; Mardekian J; Mychaskiw MA; Thomas J
    Clinicoecon Outcomes Res; 2018; 10():693-703. PubMed ID: 30464562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
    Chebib FT; Zhou X; Garbinsky D; Davenport E; Nunna S; Oberdhan D; Fernandes A
    Kidney Med; 2023 Jun; 5(6):100639. PubMed ID: 37250503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
    Perrone RD; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Gansevoort RT
    Kidney Med; 2022 Oct; 4(10):100538. PubMed ID: 36204243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More dissimilarities than affinities between DNAJB11-PKD and ADPKD.
    Pisani I; Allinovi M; Palazzo V; Zanelli P; Gentile M; Farina MT; Giuliotti S; Cravedi P; Delsante M; Maggiore U; Fiaccadori E; Manenti L
    Clin Kidney J; 2022 Jun; 15(6):1179-1187. PubMed ID: 35664268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
    Girardat-Rotar L; Puhan MA; Braun J; Serra AL
    J Nephrol; 2018 Feb; 31(1):87-94. PubMed ID: 28386880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease.
    Kim H; Koh J; Park SK; Oh KH; Kim YH; Kim Y; Ahn C; Oh YK
    Nephrology (Carlton); 2019 Apr; 24(4):422-429. PubMed ID: 29797773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.
    Cornec-Le Gall E; Audrézet MP; Renaudineau E; Hourmant M; Charasse C; Michez E; Frouget T; Vigneau C; Dantal J; Siohan P; Longuet H; Gatault P; Ecotière L; Bridoux F; Mandart L; Hanrotel-Saliou C; Stanescu C; Depraetre P; Gie S; Massad M; Kersalé A; Séret G; Augusto JF; Saliou P; Maestri S; Chen JM; Harris PC; Férec C; Le Meur Y
    Am J Kidney Dis; 2017 Oct; 70(4):476-485. PubMed ID: 28356211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment for patients with autosomal dominant polycystic kidney disease in the chronic kidney disease without kidney replacement therapy in real-world clinical practice: a descriptive retrospective cohort study.
    Sakoda K; Mizuno K; Seki T; Shinkawa K; Kawai Y; Hayashi A; Yoshida S; Takeuchi M; Yanagita M; Kawakami K
    Ann Clin Epidemiol; 2024; 6(2):33-41. PubMed ID: 38606040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.
    Rodríguez RM; Luis-Lima S; Fernandez JM; Gómez MVP; Toledo BG; Cobo M; Delgado-Mallén P; Escamilla B; Marco CO; Estupiñán S; Perera CC; Mena NN; Martín LD; Reyes SP; González IH; González-Rinne F; González-Delgado A; Ferrer-Moure C; Zulueta BL; Torres A; Rodriguez Pérez JC; Gaspari F; Ortiz A; Porrini E
    J Nephrol; 2022 Nov; 35(8):2109-2118. PubMed ID: 35357684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attitudes in Patients with Autosomal Dominant Polycystic Kidney Disease Toward Prenatal Diagnosis and Preimplantation Genetic Diagnosis.
    Swift O; Vilar E; Rahman B; Side L; Gale DP
    Genet Test Mol Biomarkers; 2016 Dec; 20(12):741-746. PubMed ID: 27689416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.